Skip to main content
×
Home
    • Aa
    • Aa
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 31
  • Cited by
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.

    McCormack, Paul L. and Joura, Elmar A. 2010. Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (Gardasil®). Drugs, Vol. 70, Issue. 18, p. 2449.


    Simonella, Leonardo and Canfell, Karen 2015. Development of a quality framework for models of cervical screening and its application to evaluations of the cost-effectiveness of HPV vaccination in developed countries. Vaccine, Vol. 33, Issue. 1, p. 34.


    Woo, Yin Ling and Omar, Siti Z. 2011. Human papillomavirus vaccination in the resourced and resource-constrained world. Best Practice & Research Clinical Obstetrics & Gynaecology, Vol. 25, Issue. 5, p. 597.


    Raymakers, Adam J.N. Sadatsafavi, Mohsen Marra, Fawziah and Marra, Carlo A. 2012. Economic and Humanistic Burden of External Genital Warts. PharmacoEconomics, Vol. 30, Issue. 1, p. 1.


    Seto, Katherine Marra, Fawziah Raymakers, Adam and Marra, Carlo A. 2012. The Cost Effectiveness of Human Papillomavirus Vaccines. Drugs, Vol. 72, Issue. 5, p. 715.


    Herdman, Michael Cole, Amanda Hoyle, Christopher K. Coles, Victoria Carroll, Stuart and Devlin, Nancy 2016. Sources and Characteristics of Utility Weights for Economic Evaluation of Pediatric Vaccines: A Systematic Review. Value in Health, Vol. 19, Issue. 2, p. 255.


    Olsen, Jens and Jørgensen, Tine Rikke 2015. Revisiting the cost-effectiveness of universal HPV-vaccination in Denmark accounting for all potentially vaccine preventable HPV-related diseases in males and females. Cost Effectiveness and Resource Allocation, Vol. 13, Issue. 1,


    Horn, J. Damm, O. Kretzschmar, M.E.E. Deleré, Y. Wichmann, O. Kaufmann, A.M. Garbe, E. Krämer, A. Greiner, W. and Mikolajczyk, R.T. 2013. Estimating the long-term effects of HPV vaccination in Germany. Vaccine, Vol. 31, Issue. 19, p. 2372.


    Rochau, Ursula Sroczynski, Gaby Wolf, Dominik Schmidt, Stefan Jahn, Beate Kluibenschaedl, Martina Conrads-Frank, Annette Stenehjem, David Brixner, Diana Radich, Jerald Gastl, Günther and Siebert, Uwe 2015. Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia. Leukemia & Lymphoma, Vol. 56, Issue. 8, p. 2315.


    Bresse, Xavier Goergen, Christoph Prager, Bernhard and Joura, Elmar 2014. Universal vaccination with the quadrivalent HPV vaccine in Austria: impact on virus circulation, public health and cost–effectiveness analysis. Expert Review of Pharmacoeconomics & Outcomes Research, Vol. 14, Issue. 2, p. 269.


    Nagoski, Emily Janssen, Erick Lohrmann, David and Nichols, Eric 2012. Risk, Individual Differences, and Environment: An Agent-Based Modeling Approach to Sexual Risk-Taking. Archives of Sexual Behavior, Vol. 41, Issue. 4, p. 849.


    Tully, Stephen P. Anonychuk, Andrea M. Maria Sanchez, Diana Galvani, Alison P. and Bauch, Chris T. 2012. Time for change? An economic evaluation of integrated cervical screening and HPV immunization programs in Canada. Vaccine, Vol. 30, Issue. 2, p. 425.


    Burger, Emily A. Sy, Stephen Nygård, Mari Kristiansen, Ivar S. and Kim, Jane J. 2015. Too Late to Vaccinate? The Incremental Benefits and Cost-effectiveness of a Delayed Catch-up Program Using the 4-Valent Human Papillomavirus Vaccine in Norway. Journal of Infectious Diseases, Vol. 211, Issue. 2, p. 206.


    Rochau, Ursula Sroczynski, Gaby Wolf, Dominik Schmidt, Stefan Conrads-Frank, Annette Jahn, Beate Saverno, Kim Brixner, Diana Radich, Jerald Gastl, Guenther and Siebert, Uwe 2014. Medical decision analysis for first-line therapy of chronic myeloid leukemia. Leukemia & Lymphoma, Vol. 55, Issue. 8, p. 1758.


    Olsen, Jens Jørgensen, Tine Rikke Kofoed, Kristian and Larsen, Helle Kiellberg 2012. Incidence and cost of anal, penile, vaginal and vulvar cancer in Denmark. BMC Public Health, Vol. 12, Issue. 1,


    Mauskopf, Josephine Talbird, Sandra and Standaert, Baudouin 2012. Categorization of methods used in cost–effectiveness analyses of vaccination programs based on outcomes from dynamic transmission models. Expert Review of Pharmacoeconomics & Outcomes Research, Vol. 12, Issue. 3, p. 357.


    Olsen, Jens Jørgensen, Tine Rikke and Rubek, Niclas 2013. The Economic Burden of Head and Neck Cancers in Denmark. International Journal of Otolaryngology and Head & Neck Surgery, Vol. 02, Issue. 03, p. 103.


    Jiang, Yiling Gauthier, Aline Postma, Maarten J Ribassin-Majed, Laureen Largeron, Nathalie and Bresse, Xavier 2013. A critical review of cost-effectiveness analyses of vaccinating males against human papillomavirus. Human Vaccines & Immunotherapeutics, Vol. 9, Issue. 11, p. 2285.


    Canfell, Karen Chesson, Harrell Kulasingam, Shalini L. Berkhof, Johannes Diaz, Mireia and Kim, Jane J. 2012. Modeling Preventative Strategies against Human Papillomavirus-Related Disease in Developed Countries. Vaccine, Vol. 30, p. F157.


    McCormack, Paul L. and Joura, Elmar A. 2011. Spotlight on Quadrivalent Human Papillomavirus(Types 6, 11, 16, 18) Recombinant Vaccine(Gardasil®) in the Prevention of PremalignantGenital Lesions, Genital Cancer, and Genital Warts in Women†. BioDrugs, Vol. 25, Issue. 5, p. 339.


    ×
  • International Journal of Technology Assessment in Health Care, Volume 26, Issue 2
  • April 2010, pp. 183-191

Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark

  • Jens Olsen (a1) and Martin Rudbeck Jepsen (a2)
  • DOI: http://dx.doi.org/10.1017/S0266462310000085
  • Published online: 15 April 2010
Abstract

Objectives: The objective of this study was to simulate human papillomavirus (HPV) infection in a heterosexual population and subsequently analyze the incremental costs and effects of introducing a vaccination program against HPV types 6, 11, 16, and 18 in Denmark compared with screening alone.

Methods: The analysis was performed in two phases. First, an agent-based transmission model was developed that described the HPV transmission without and with HPV vaccination. Second, an analysis of the incremental costs and effects was performed. The results of prevalence estimates of HPV, genital warts, cervical intraepithelial neoplasia (CIN1–3), and cervical cancer in the model simulations before and after introduction of HPV vaccination were extrapolated to the Danish population figures. Incremental costs and effects were then estimated. Future costs and effects were discounted.

Results: Cost-effectiveness ratios for annual vaccination of 12-year-old girls, with a vaccination rate of 70 percent without a catch-up program, were estimated at approximately €1,917 per quality-adjusted life-year (QALY, 3 percent discount rate) and €10,846/QALY (5 percent discount rate), given a 62-year time horizon.

Conclusions: A vaccination program would incur extra vaccination costs but would save treatment costs and improve both quality of life and survival.

Copyright
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

2.AN Burchell , H Richardson , SM Mahmud , Modeling the sexual transmissibility of human papillomavirus infection using stochastic computer simulation and empirical data from a cohort study of young women in Montreal, Canada. Am J Epidemiol. 2006;163:534543.

4.GM Clifford , RK Rana , S Franceschi , Human papillomavirus genotype distribution in low-grade cervical lesions: Comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:11571164.

5.EH Elbasha , EJ Dasbach , RP Insinga . Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis. 2007;13:2841.

7.D Hu , S Goldie . The economic burden of noncervical human papillomavirus disease in the United States. Am J Obstet Gynecol. 2008;198:500507.

9.M Jit , YH Choi , WJ Edmunds . Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ. 2008;337:a769.

10.SY Kim , SJ Goldie . Cost-effectiveness analyses of vaccination programmes: A focused review of modelling approaches. Pharmacoeconomics. 2008;26:191215.

11.SK Kjaer , TN Tran , P Sparen , The burden of genital warts: A study of nearly 70,000 women from the general female population in the 4 Nordic countries. J Infect Dis. 2007;196:14471454.

12.CJ Lacey , CM Lowndes , KV Shah . Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine. 2006;24 (Suppl 3):S35S41.

20.SE Olsson , LL Villa , RL Costa , Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine. 2007;25:49314939.

21.DM Parkin , F Bray , J Ferlay , P Pisani . Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74108.

22.JS Smith , L Lindsay , B Hoots , Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis update. Int J Cancer. 2007;121:621632.

24.C Usher , L Tilson , J Olsen , Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model. Vaccine. 2008;26:56545661.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

International Journal of Technology Assessment in Health Care
  • ISSN: 0266-4623
  • EISSN: 1471-6348
  • URL: /core/journals/international-journal-of-technology-assessment-in-health-care
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords: